Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $1200
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1125 to $1200.
August 02, 2024 | 6:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $1125 to $1200.
The increase in price target from $1125 to $1200 by a reputable analyst at Wells Fargo is a positive signal for investors, indicating confidence in Regeneron's future performance. This is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100